4.6 Article

A negative feedback loop between miR-200b and the nuclear factor-κB pathway via IKBKB/IKK-β in breast cancer cells

Journal

FEBS JOURNAL
Volume 283, Issue 12, Pages 2259-2271

Publisher

WILEY
DOI: 10.1111/febs.13543

Keywords

breast cancer cells; IKBKB; microRNA; miR-200b; nuclear factor-kappa B (NF-kappa B)

Funding

  1. project 'The molecular mechanism of Erlin2 in breast cancer cell growth and regulating drug resistant to Herceptin targeting therapy'

Ask authors/readers for more resources

MicroRNAs (miRNAs) act as important post-transcriptional regulators of gene expression in diverse signalling pathways. However, the relationship between miR-200b and the nuclear factor-kappa B (NF-kappa B) signalling pathway remains poorly understood in breast cancer cells. In the current study, we show that IKBKB is a direct target of miR-200b, and that miR-200b downregulates IKBKB expression via directly binding to its 3 '-UTR. miR-200b inhibits I kappa B alpha phosphorylation, nuclear p50/p65 expression, NF-kappa B-binding activity, and the translocation of p65 to the nucleus. In addition, miR-200b also suppresses tumour necrosis factor (TNF)-alpha-induced NF-kappa B activation and the expression of NF-kappa B target genes. Importantly, IKBKB overexpression attenuates the inhibitory roles of miR-200b in NF-kappa B expression, NF-kappa B-binding activity, and the nuclear translocation of p65. We also show that NF-kappa B p65 knockdown reduces the binding of NF-kappa B to the miR-200b promoter and miR-200b promoter activity. Furthermore, p65 knockdown or inhibition of I kappa B alpha phosphorylation suppresses miR-200b expression. Finally, functional studies show that IKBKB overexpression can restore the cell growth and migration that are suppressed by miR-200b. In conclusion, our results demonstrate that miR-200b, a transcriptional target of NF-kappa B, suppresses breast cancer cell growth and migration, and NF-kappa B activation, through downregulation of IKBKB, indicating that miR-200b has potential as a therapeutic target in breast cancer patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available